Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.

Doubková M, Švancara J, Svoboda M, Šterclová M, Bartoš V, Plačková M, Lacina L, Žurková M, Binková I, Bittenglová R, Lošťáková V, Merta Z, Šišková L, Tyl R, Lisá P, Šuldová H, Petřík F, Pšikalová J, Řihák V, Snížek T, Reiterer P, Homolka J, Musilová P, Lněnička J, Palúch P, Hrdina R, Králová R, Hortvíková H, Strenková J, Vašáková M.

Clin Respir J. 2018 Apr;12(4):1526-1535. doi: 10.1111/crj.12700. Epub 2017 Sep 26.

PMID:
28862397
2.

Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG; ARTEMIS-IPF Investigators*.

Ann Intern Med. 2013 May 7;158(9):641-9. doi: 10.7326/0003-4819-158-9-201305070-00003. Erratum in: Ann Intern Med. 2014 May 6;160(9):658.

PMID:
23648946
3.

HDR intraluminal brachytherapy in the treatment of malignant bronchial obstructions.

Petera J, Neumanová R, Vrba M, Coupek P, Salajka F, Hrazdírová A, Kucera M, Snízek T, Kolman P, Hanák V.

Neoplasma. 2000;47(1):56-9.

PMID:
10870688

Supplemental Content

Loading ...
Support Center